Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson to Combine Industry-Leading AI with World-Class Drug Development in Cross-Modality Strategic Partnership

LONDON, 20 January, 2026 - Isomorphic Labs today announced a cross-modality, multi-target research collaboration with Johnson & Johnson*. This partnership brings together Isomorphic's AI-first approach to drug discovery with Johnson & Johnson's expertise in drug discovery and development.

Under the collaboration structure, Isomorphic Labs will be responsible for in silico predictions and design while Johnson & Johnson will conduct experimental assays and assume responsibility for advancing programs.

Isomorphic Labs' foundational drug design engine is capable of generating drug candidates against challenging targets across a range of modalities such as small molecules, antibodies, peptides and molecular glues. This collaboration will leverage this multi-modality discovery capability, including large molecule and biologics design.

"This partnership combines Isomorphic Labs' pioneering AI capabilities with Johnson & Johnson's expertise in target biology and drug discovery," said Sarah Skerratt PhD, Chief Research Officer, Isomorphic Labs. "This collaboration is about more than speed; it is about unlocking uncharted frontiers in biology. By accessing Isomorphic's planet-scale computing power and unified AI-driven drug design engine, the partnership will tackle targets that have historically been difficult to drug."

By building powerful predictive and generative models of biological systems, Isomorphic Labs aims to design novel molecules that might otherwise remain undiscovered. This AI-first approach allows the company to more deeply understand the underlying biological mechanisms of drug targets and rationally design therapeutic candidates.

**Legal entity: Janssen Biotech, Inc.*

About Isomorphic Labs

Isomorphic Labs was founded in 2021, with a mission to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by AI pioneer Sir Demis Hassabis, and its founding was built on the Nobel-winning AI breakthrough, AlphaFold. Isomorphic Labs, together with Google DeepMind, developed and released AlphaFold 3 in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life's molecules with

unprecedented accuracy. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has office locations in Lausanne, Switzerland and Cambridge, Massachusetts. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs. For more information, go to www.isomorphiclabs.com and follow us on LinkedIn and X.
For Media enquiries press@isomorphiclabs.com